Cat. No.: HY-N0156

Copy Link Print Information

Oleanolic acid

(Synonyms: Oleanic acid; Caryophyllin)

21 Cited Publications

Customer Review

Based on 21 publication(s) in Google Scholar

Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.

For research use only. We do not sell to patients.

Purity: 99.71%
CAS No.: 508-02-1
Formula: C₃₀H₄₈O₃
Molecular Weight:456.70

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Oleanolic acid Chemical Structure

CAS No.: 508-02-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (21)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.

IC₅₀ & Target

ASK1	Influenza hemagglutinin (HA)

All MAP3K Isoforms :

All Endogenous Metabolite Isoforms :

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	514.1 μM Compound: 3; OA	Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
518A2	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 28033541]
518A2	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
518A2	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
518A2	EC₅₀	61.3 μM Compound: OA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
518A2	EC₅₀	64.3 μM Compound: 1; OA	Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
518A2	EC₅₀	64.3 μM Compound: OA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 26750249]
518A2	IC₅₀	>60 μM Compound: OA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24361521]
8505C	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 28033541]
8505C	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
8505C	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
8505C	IC₅₀	>60 μM Compound: OA	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A2780	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
A2780	EC₅₀	14 μM Compound: 1; OA	Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
A2780	EC₅₀	14 μM Compound: 2	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 28033541]
A2780	EC₅₀	14 μM Compound: OA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 26750249]
A2780	EC₅₀	58.2 μM Compound: OA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
A2780	IC₅₀	>=20 μg/mL Compound: 10	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 12662105]
A2780	IC₅₀	14 μM Compound: OA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	IC₅₀	8 μg/mL Compound: oleanolic acid	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 15217279]
A-375	IC₅₀	328.8 μM Compound: 3; OA	Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 28033541]
A549	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
A549	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A549	EC₅₀	64.1 μM Compound: OA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
A549	EC₅₀	72.3 μM Compound: 1; OA	Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
A549	EC₅₀	72.3 μM Compound: OA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 26750249]
A549	GI₅₀	>100 μM Compound: 27	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
A549	IC₅₀	>100 μM Compound: 1, oleanolic acid	Cytotoxicity against human A549 cells after 1 hr by MTT assay Cytotoxicity against human A549 cells after 1 hr by MTT assay	[PMID: 18343122]
A549	IC₅₀	>100 μM Compound: OA	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	>200 μM Compound: 4	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
A549	IC₅₀	0.39 μM Compound: 1, OA	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23434227]
A549	IC₅₀	16.29 μM Compound: 1	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
A549	IC₅₀	19.94 μM Compound: OA	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
A549	IC₅₀	209 μM Compound: 10	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 15730243]
A549	IC₅₀	27 μM Compound: 4	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
A549	IC₅₀	41.65 μM Compound: 1; OA	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
A549	IC₅₀	6.4 μM Compound: OA	Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay	[PMID: 31718182]
A549	IC₅₀	64.26 μM Compound: 3; OA	Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	IC₅₀	72.3 μM Compound: OA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24361521]
A549	IC₅₀	81.4 μM Compound: OA	Cytotoxicity against human A549 cells after 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 24422538]
A549	IC₅₀	96.2 μM Compound: 10	Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge	[PMID: 15730243]
A549/TR	IC₅₀	>200 μM Compound: 1; OA	Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
B16	IC₅₀	4.8 μM Compound: 18	Growth inhibition of mouse B16 2F2 cells after 3 days Growth inhibition of mouse B16 2F2 cells after 3 days	[PMID: 12027734]
B16-F10	IC₅₀	106.4 μM Compound: 1, OA, Oleanolic acid	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 24480359]
B16-F10	IC₅₀	106.4 μM Compound: I, Oleanolic acid	Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 29471121]
B16-F10	IC₅₀	106.4 μM Compound: I; OA; Oleanolic and	Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
B16-F10	IC₅₀	106.4 μM Compound: OA	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
B16-F10	IC₅₀	388.3 μM Compound: 3; OA	Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
Bel-7402	IC₅₀	59.94 μM Compound: 1; OA	Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
Bel7402/5-FU	IC₅₀	>200 μM Compound: 1; OA	Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
BEL-7404 tumor cell line	IC₅₀	57.89 μM Compound: 1, OA	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	10.1039/C2MD20051A
BGC-823	IC₅₀	2.59 μM Compound: 1, OA	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23434227]
BGC-823	IC₅₀	23.74 μM Compound: 1	Cytotoxicity against human BGC823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
BMDC	IC₅₀	>50 μM Compound: 22	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
BMDC	IC₅₀	>50 μM Compound: 22	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
BMDC	IC₅₀	>50 μM Compound: 22	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
CAPAN-1	IC₅₀	50.1 μM Compound: OA	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
CHO	EC₅₀	2.25 μM Compound: 2	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COLO 205	IC₅₀	>10 μM Compound: 6	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 30199257]
COLO 320	IC₅₀	>10 μM Compound: 6	Cytotoxicity against human COLO320 cells after 24 hrs by MTT assay Cytotoxicity against human COLO320 cells after 24 hrs by MTT assay	[PMID: 30199257]
COS-1	EC₅₀	0 μM Compound: 2	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
DLD-1	IC₅₀	>100 μM Compound: 4	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
DLD-1	IC₅₀	>200 μM Compound: 4	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
DU-145	CC₅₀	65.6 μM Compound: 10	Cytotoxic activity in human DU145 cells by sulforhodamine B assay Cytotoxic activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	IC₅₀	124 μM Compound: 10	Antiproliferative activity in human DU145 cells by sulforhodamine B assay Antiproliferative activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
FaDu	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
FaDu	EC₅₀	66.7 μM Compound: OA	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
FaDu	EC₅₀	75.4 μM Compound: 1; OA	Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
FaDu	EC₅₀	75.4 μM Compound: OA	Cytotoxicity against human FADU cells after 96 hrs by SRB assay Cytotoxicity against human FADU cells after 96 hrs by SRB assay	[PMID: 26750249]
H9	EC₅₀	1.7 μg/mL Compound: 1	Cytotoxicity against mock-infected human H9 cells after 4 days Cytotoxicity against mock-infected human H9 cells after 4 days	[PMID: 9748372]
H9	EC₅₀	1.7 μg/mL Compound: 1	Antiviral activity against HIV-1(IIIB) infected H9 cell lines. Antiviral activity against HIV-1(IIIB) infected H9 cell lines.	[PMID: 11720855]
H9	EC₅₀	3.7 μM Compound: 3	Cytotoxicity against mock-infected human H9 cells Cytotoxicity against mock-infected human H9 cells	[PMID: 11141100]
H9	IC₅₀	21.8 μg/mL Compound: 1	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
H9	IC₅₀	21.8 μg/mL Compound: 1	Concentration which was toxic to 50% of the mock-infected H9 lymphocyte. Concentration which was toxic to 50% of the mock-infected H9 lymphocyte.	[PMID: 11720855]
H9	IC₅₀	47.8 μM Compound: 3	Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days	[PMID: 11141100]
HCT-116	GI₅₀	>100 μM Compound: 27	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
HCT-116	IC₅₀	>150 μM Compound: OA	Cytotoxicity against human HCT116 cells after 48 hrs by CCK-8 assay Cytotoxicity against human HCT116 cells after 48 hrs by CCK-8 assay	[PMID: 24422538]
HCT-116	IC₅₀	32.4 μM Compound: OA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
HCT-116	IC₅₀	4.8 μM Compound: Oleanolic acid	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 20951582]
HEK293	CC₅₀	>500 μM Compound: 10	Cytotoxic activity in HEK293 cells by sulforhodamine B assay Cytotoxic activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	>500 μM Compound: 10	Antiproliferative activity in HEK293 cells by sulforhodamine B assay Antiproliferative activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	329 μM Compound: 9	Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by cell titer-blue assay Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by cell titer-blue assay	[PMID: 26473275]
HEL	EC₅₀	>1 μM Compound: OA	Antiproliferative activity against human HEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33569941]
HeLa	CC₅₀	>500 μM Compound: 10	Cytotoxic activity in human HeLa cells by sulforhodamine B assay Cytotoxic activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	>100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24487188]
HeLa	IC₅₀	>100 μM Compound: OA	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HeLa	IC₅₀	>30 μM Compound: OA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38039788]
HeLa	IC₅₀	204.5 μM Compound: 10	Antiproliferative activity in human HeLa cells by sulforhodamine B assay Antiproliferative activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	31.38 μM Compound: OA	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HeLa	IC₅₀	4 μM Compound: 1	Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs	[PMID: 21561086]
HEp-2	CC₅₀	>500 μM Compound: 10	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	>500 μM Compound: 10	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HepG2	IC₅₀	>10 μM Compound: 16	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27797185]
HepG2	IC₅₀	>100 μM Compound: 11	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
HepG2	IC₅₀	>200 μM Compound: OA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
HepG2	IC₅₀	>280 μM Compound: 4b	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 25442310]
HepG2	IC₅₀	>30 μM Compound: OA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38039788]
HepG2	IC₅₀	14.72 μM Compound: OA	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HepG2	IC₅₀	15.9 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
HepG2	IC₅₀	165 μM Compound: 10	Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
HepG2	IC₅₀	211.8 μM Compound: I, Oleanolic acid	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 29471121]
HepG2	IC₅₀	211.8 μM Compound: I; OA; Oleanolic and	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
HepG2	IC₅₀	211.8 μM Compound: OA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
HepG2	IC₅₀	51.4 μM Compound: OA	Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay	[PMID: 24422538]
HepG2 2.2.15	CC₅₀	731.2 μM Compound: D1; OA	Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 29627260]
HL-60	IC₅₀	>30 μM Compound: 1; OA	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29133061]
HL-60	IC₅₀	>50 μg/mL Compound: oleanolic acid	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 10514313]
HL-60	IC₅₀	14.75 μM Compound: 1; OA	Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
HL-60	IC₅₀	16.17 μM Compound: OA	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HL-60	IC₅₀	36.4 μM Compound: OA	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
HL-60	IC₅₀	54.56 μM Compound: 1, OA	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	10.1039/C2MD20051A
HL-60	IC₅₀	77.48 μM Compound: Oleanolic acid	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 20951582]
HL60/ADR	IC₅₀	28.75 μM Compound: 1; OA	Cytotoxicity in human HL60/ADR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HL60/ADR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
HSC-T6	EC₅₀	59.6 nM Compound: 139	Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay	[PMID: 29353722]
HT-29	EC₅₀	>10 μM Compound: 8	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 33248849]
HT-29	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 28033541]
HT-29	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
HT-29	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
HT-29	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
HT-29	EC₅₀	38.8 μM Compound: 1; OA	Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
HT-29	EC₅₀	38.8 μM Compound: OA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 26750249]
HT-29	EC₅₀	44.9 μM Compound: OA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
HT-29	IC₅₀	>10 μM Compound: 8	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
HT-29	IC₅₀	>10 μM Compound: 8	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
HT-29	IC₅₀	>100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 24487188]
HT-29	IC₅₀	>30 μM Compound: 1; OA	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29133061]
HT-29	IC₅₀	38.8 μM Compound: OA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24361521]
HT-29	IC₅₀	429.9 μM Compound: I, Oleanolic acid	Growth inhibition of human HT-29 cells after 72 hrs by MTT assay Growth inhibition of human HT-29 cells after 72 hrs by MTT assay	[PMID: 29471121]
HT-29	IC₅₀	429.9 μM Compound: I; OA; Oleanolic and	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
HT-29	IC₅₀	429.9 μM Compound: OA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
J774	IC₅₀	130.5 μM Compound: 8	Cytotoxicity against mouse J774 cells by alamar blue assay Cytotoxicity against mouse J774 cells by alamar blue assay	[PMID: 17637068]
J774.A1	IC₅₀	35.2 μM Compound: 1, Oleanolic acid	Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
J774.A1	IC₅₀	87.22 μM Compound: 1, Oleanolic acid	Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control	[PMID: 25113933]
Jurkat	EC₅₀	>1 μM Compound: OA	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33569941]
K562	EC₅₀	>100 μM Compound: OA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33569941]
K562	IC₅₀	>100 μM Compound: OA	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
K562	IC₅₀	>200 μM Compound: 1; OA	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
K562	IC₅₀	58.13 μM Compound: 1, OA	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	10.1039/C2MD20051A
K562/Adr	IC₅₀	>200 μM Compound: 1; OA	Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
KB	CC₅₀	>500 μM Compound: 10	Cytotoxic activity in human KB cells by sulforhodamine B assay Cytotoxic activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	>10 μM Compound: OA	Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
KB	IC₅₀	>100 μM Compound: 11	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
KB	IC₅₀	>280 μM Compound: 4b	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 25442310]
KB	IC₅₀	>500 μM Compound: 10	Antiproliferative activity in human KB cells by sulforhodamine B assay Antiproliferative activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
L02	IC₅₀	>200 μM Compound: 1; OA	Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
L02	IC₅₀	>200 μM Compound: OA	Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
L5178Y	IC₅₀	>10 μM Compound: 6	Antiproliferative activity against mouse L5178Y cells after 72 hrs by MTT assay Antiproliferative activity against mouse L5178Y cells after 72 hrs by MTT assay	[PMID: 30199257]
L5178Y	IC₅₀	>10 μM Compound: 6	Antiproliferative activity against mouse L5178Y cells harboring human ABCB1 after 72 hrs by MTT assay Antiproliferative activity against mouse L5178Y cells harboring human ABCB1 after 72 hrs by MTT assay	[PMID: 30199257]
Lewis lung carcinoma cell line	IC₅₀	>150 μM Compound: 9	Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay	[PMID: 19618898]
Lewis lung carcinoma cell line	IC₅₀	810.1 μM Compound: 3; OA	Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
LN-229	IC₅₀	>100 μM Compound: OA	Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
Lu1	IC₅₀	>100 μM Compound: 11	Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
M14	IC₅₀	82 μM Compound: 5	Cytotoxicity against human M14 cells after 48 hrs by MTT assay Cytotoxicity against human M14 cells after 48 hrs by MTT assay	[PMID: 21954959]
Macrophage	CC₅₀	29.69 μM Compound: Oleanolic acid	Cytotoxicity against BALB/c mouse bone-marrow derived macrophage cells assessed as reduction in cell viability incubated for 11 days by MTT assay Cytotoxicity against BALB/c mouse bone-marrow derived macrophage cells assessed as reduction in cell viability incubated for 11 days by MTT assay	[PMID: 36701870]
Macrophage	IC₅₀	>40 μM Compound: 3	Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method	[PMID: 23837912]
Macrophage	IC₅₀	18.64 μM Compound: Oleanolic acid	Anti-osteoclastogensis activity in BALB/c mouse bone marrow macrophage cells assessed as inhibition of RANKL/M-CSF-induced osteoclastogenesis by measuring osteoclasts number incubated for 11 days by TRAP staining based assay Anti-osteoclastogensis activity in BALB/c mouse bone marrow macrophage cells assessed as inhibition of RANKL/M-CSF-induced osteoclastogenesis by measuring osteoclasts number incubated for 11 days by TRAP staining based assay	[PMID: 36701870]
MCF-12A	IC₅₀	>50 μM Compound: 1; OA	Cytotoxicity in human MCF12A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MCF12A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MCF7	CC₅₀	>500 μM Compound: 10	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 28033541]
MCF7	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
MCF7	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
MCF7	EC₅₀	>30 μM Compound: OA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
MCF7	EC₅₀	49.1 μM Compound: OA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
MCF7	EC₅₀	80 μM Compound: 1; OA	Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
MCF7	EC₅₀	80 μM Compound: OA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 26750249]
MCF7	GI₅₀	>100 μM Compound: 27	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32345458]
MCF7	GI₅₀	10.3 μM Compound: 1; OA	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MCF7	IC₅₀	>10 μM Compound: 16	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27797185]
MCF7	IC₅₀	>10 μM Compound: OA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MCF7	IC₅₀	>100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24487188]
MCF7	IC₅₀	>100 μM Compound: 11	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	IC₅₀	>100 μM Compound: OA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	>150 μM Compound: 9	Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19618898]
MCF7	IC₅₀	>150 μM Compound: OA	Cytotoxicity against human MCF7 cells after 48 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 24422538]
MCF7	IC₅₀	>200 μM Compound: 1; OA	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
MCF7	IC₅₀	>30 μM Compound: OA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38039788]
MCF7	IC₅₀	>500 μM Compound: 10	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	>60 μM Compound: OA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24361521]
MCF7	IC₅₀	12.6 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
MCF7	IC₅₀	12.7 μM Compound: 1; OA	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MCF7	IC₅₀	35.4 μM Compound: 1, OA	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 23434227]
MCF7	IC₅₀	4.23 nM Compound: 52; OA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37847948]
MDA-MB-231	CC₅₀	106 μM Compound: 10	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	GI₅₀	17.6 μM Compound: 1; OA	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MDA-MB-231	IC₅₀	>10 μM Compound: 8	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-231	IC₅₀	>10 μM Compound: OA	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MDA-MB-231	IC₅₀	>100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24487188]
MDA-MB-231	IC₅₀	>30 μM Compound: OA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38039788]
MDA-MB-231	IC₅₀	>50 μM Compound: 1; OA	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MDA-MB-231	IC₅₀	134 μM Compound: 10	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	512.4 μM Compound: 3; OA	Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
MDA-MB-231	IC₅₀	67.87 μM Compound: 1, OA	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	10.1039/C2MD20051A
MDA-MB-435	IC₅₀	>10 μM Compound: 8	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-453	IC₅₀	>100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay	[PMID: 24487188]
MDA-MB-468	IC₅₀	38.1 μM Compound: 1; OA	Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MDCK	CC₅₀	>100 μM Compound: OA	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay	[PMID: 31425909]
MDCK	CC₅₀	>100 μM Compound: OA	Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay	[PMID: 34795865]
MDCK	CC₅₀	>100 μM Compound: OA	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by celltiter-glo assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by celltiter-glo assay	[PMID: 37354741]
MDCK	CC₅₀	23.1 μM Compound: OA	Cytotoxicity against MDCK cells assessed as cell death after 2 days by MTT assay Cytotoxicity against MDCK cells assessed as cell death after 2 days by MTT assay	[PMID: 27153348]
MDCK	IC₅₀	>50 μM Compound: OA	Antiviral activity against Influenza A virus A/Thailand/Kan353/2004(H5N1) pseudovirus infected in MDCK cells co-infected with HA/HIV assessed as inhibition of viral replication preincubated with virus for 30 mins followed by viral infection for 48 hrs by Antiviral activity against Influenza A virus A/Thailand/Kan353/2004(H5N1) pseudovirus infected in MDCK cells co-infected with HA/HIV assessed as inhibition of viral replication preincubated with virus for 30 mins followed by viral infection for 48 hrs by	[PMID: 27153348]
ME-180	IC₅₀	>100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human ME180 cells after 48 hrs by MTT assay Cytotoxicity against human ME180 cells after 48 hrs by MTT assay	[PMID: 24487188]
MGC-803	IC₅₀	>200 μM Compound: OA	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
MRC5	IC₅₀	>10 μM Compound: 6	Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay	[PMID: 30199257]
NCI/ADR-RES	IC₅₀	>200 μM Compound: 1; OA	Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
NCI-H1975	IC₅₀	>10 μM Compound: OA	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	>10 μM Compound: OA	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H460	IC₅₀	>100 μM Compound: OA	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
NCI-N87	IC₅₀	>10 μM Compound: 16	Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay	[PMID: 27797185]
Neutrophil	IC₅₀	0.75 μM Compound: 15	Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins	[PMID: 21417387]
Neutrophil	IC₅₀	1.37 μM Compound: 15	Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils	[PMID: 21417387]
NIH3T3	EC₅₀	>30 μM Compound: 2	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 28033541]
NIH3T3	EC₅₀	>30 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
NIH3T3	EC₅₀	>30 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
NIH3T3	EC₅₀	57.9 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
NIH3T3	EC₅₀	76.4 μM Compound: 1; OA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
NIH3T3	EC₅₀	76.4 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 26750249]
NIH3T3	IC₅₀	>10 μM Compound: 6	Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay	[PMID: 30199257]
NIH3T3	IC₅₀	76.4 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24361521]
OVCAR-3	IC₅₀	>10 μM Compound: 8	Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
PANC-1	IC₅₀	362.8 μM Compound: 3; OA	Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
PC-12	EC₅₀	8.55 μM Compound: 1	Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells	[PMID: 31924497]
PC-3	IC₅₀	>100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24487188]
PC-3	IC₅₀	>30 μM Compound: 1; OA	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29133061]
PC-3	IC₅₀	211 μM Compound: 8	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 16441066]
PC-3	IC₅₀	6.51 μM Compound: 1, OA	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 23434227]
PC-3	IC₅₀	72.74 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
Raji	IC₅₀	389 molar ratio Compound: oleanolic acid	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation	[PMID: 18387711]
Raji	IC₅₀	449 nM Compound: Oleanolic acid	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs	[PMID: 21620532]
Raji	IC₅₀	449 molar ratio Compound: Oleanolic acid	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs	[PMID: 20153563]
RAW264.7	CC₅₀	145.47 μM Compound: Oleanolic acid	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36701870]
RAW264.7	IC₅₀	41.7 μM Compound: 1, Oleanolic acid	Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
RAW264.7	IC₅₀	89.12 μM Compound: 1, Oleanolic acid	Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control	[PMID: 25113933]
RAW264.7	IC₅₀	96.63 μM Compound: Oleanolic acid	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta level incubated for 48 hrs by ELISA assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta level incubated for 48 hrs by ELISA assay	[PMID: 36701870]
Sf21	IC₅₀	>40 μM Compound: 10	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]
Sf9	IC₅₀	>20 μM Compound: OA	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay	[PMID: 31718182]
Sf9	IC₅₀	>20 μM Compound: OA	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k	[PMID: 31718182]
Sf9	IC₅₀	>20 μM Compound: OA	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki	[PMID: 31718182]
SiHa	CC₅₀	108.7 μM Compound: 10	Cytotoxic activity in human SiHa cells by sulforhodamine B assay Cytotoxic activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SiHa	IC₅₀	110.2 μM Compound: 10	Antiproliferative activity in human SiHa cells by sulforhodamine B assay Antiproliferative activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SK-MEL	IC₅₀	112 μM Compound: 1	Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL	[PMID: 10450948]
SK-MEL	IC₅₀	112 μM Compound: 1	Cytotoxicity against human malignant melanoma cell line SK-MEL Cytotoxicity against human malignant melanoma cell line SK-MEL	[PMID: 11425522]
T-24	IC₅₀	66.86 μM Compound: OA	Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay	[PMID: 37742398]
T47D	IC₅₀	36.22 μM Compound: 1; OA	Cytotoxicity in human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
U-87MG ATCC	IC₅₀	18.52 μM Compound: OA	Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
Vero	CC₅₀	>500 μM Compound: 10	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Vero	IC₅₀	>250 μM Compound: 8	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 16441066]
Vero	IC₅₀	>500 μM Compound: 10	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
WI-38	IC₅₀	14.5 μM Compound: 10	Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38 VA13	IC₅₀	123 μM Compound: 10	Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
Z-138	IC₅₀	>100 μM Compound: OA	Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]

In Vitro

Oleanolic acid (OA) suppresses the proliferation of lung cancer cells in both dose- and time-dependent manners, along with an increase in miR-122 abundance. CCNG1 and MEF2D, two putative miR-122 targets, are found to be downregulated by OA treatment ^[1]. OA induces autophagy in normal tissue-derived cells without cytotoxicity. OA-induced autophagy is shown to decrease the proliferation of KRAS-transformed normal cells and to impair their invasion and anchorage-independent growth^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mouse model experiments also demonstrat that OA suppresses the growth of KRAS-transformed breast epithelial cell MCF10A-derived tumor xenograft by inducing autophagy ^[2]. Activation of MAPK pathways, including p-38 MAPK, JNK and ERK, is triggered by OA in both a dose and time-dependent fashion in all the tested cancer cells. OA induces p38 MAPK activation promoted mitochondrial translocation of Bax and Bim, and inhibits Bcl-2 function by enhancing their phosphorylation. OA can induce reactive oxygen species (ROS)-dependent ASK1 activation, and this event is indispensable for p38 MAPK-dependent apoptosis in cancer cells^[3].It is also proved that p38 MAPK knockdown A549 tumors are resistant to the growth-inhibitory effect of OA^[3]. In OA-treated EAM mice the number of Treg cells and the production of IL-10 and IL-35 are markedly increased, while proinflammatory and profibrotic cytokines are significantly reduced^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 508-02-1
Appearance Solid
Molecular Weight 456.70
Formula C₃₀H₄₈O₃
Color White to off-white
SMILES

C[C@]([C@@]1([H])[C@]2(CC[C@@H]3O)C)(CC[C@@]2([H])C3(C)C)[C@@](C4=CC1)(CC[C@]5(C(O)=O)[C@@]4([H])CC(C)(C)CC5)C
Synonyms

Oleanic acid; Caryophyllin
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (21)

All Bio/Physico-chemical AssayWBIPCell Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Allosterically activating SHP2 by oleanolic acid inhibits STAT3-Th17 axis for ameliorating colitis. [Abstract]

2024 Jun;14(6):2598-2612. PMID: 38828149

Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612. [Abstract]

Fourteen candidates were selected from 1900 FDA-approved and 30 of our own SE series compounds in primary screening for the SHP099 IC50 assay, and Oleanolic acid exhibited the best effect.

Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612. [Abstract]

Protein thermal stability analysis was performed to examine the effect of Oleanolic acid (0-100 μmol/L) on SHP2-E76K.

Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612. [Abstract]

Naive T cells from mice were treated with 30 μmol/L Oleanolic acid for different hours or various concentrations for 1 h. Protein levels were assessed by Western blot.

Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612. [Abstract]

Naive T cells from mice were treated with Oleanolic acid, followed by stimulation of IL-6 (25 ng/mL) for 30 min. Protein levels were assessed by Western blot (n = 3).

Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612. [Abstract]

Lymph node-derived T cells were treated or not with 30 μmol/L Oleanolic acid for 6 h, and the T cells were then treated with 25 ng/mL of IL-6 for 30 min. After incubation, the total protein was immunoprecipitated with an Ab against STAT3. The immunoprecipitants were assessed by Western blotting.

Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612. [Abstract]

Lymph node-derived T cells were treated with or without 30 μmol/L Oleanolic acid for 6 h, and the T cells were then treated with 25 ng/mL of IL-6 for 30 min. After treatment, the cells were analyzed by immunofluorescence. The results shown are representative of three independent experiments. Scale bar, 10 μm.

Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612. [Abstract]

Oleanolic acid ameliorated TNBS-induced experimental colitis in mice. Mice were challenged with TNBS on Day 0, and oral administration of Oleanolic acid was carried out from Days 0–4. After sacrifice on Day 4, colon damage was evaluated by colon length (n = 6).
Chem Eng J

2025 Nov 7;525:170493.
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 May 9:204:107208. PMID: 38729587
Food Chem

Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]

2023 Mar 30;405(Pt A):134807. PMID: 36370576
Phytomedicine

Bioactivity-based molecular networking-guided identification of methyl rosmarinate from Orthosiphon aristatus as a PTP1B inhibitor that improves insulin sensitivity in diabetic mice. [Abstract]

2025 Oct 21:148:157444. PMID: 41151449
Phytomedicine

Oleanolic acid inhibits M2 macrophage polarization and potentiates anti-PD-1 therapy in hepatocellular carcinoma by targeting miR-130b-3p-PTEN-PI3K-Akt signaling and glycolysis. [Abstract]

2025 Apr 9:141:156750. PMID: 40250003
Phytomedicine

Oleanolic acid inhibits hypoxic tumor-derived exosomes-induced premetastatic niche formation in hepatocellular carcinoma by targeting ERK1/2-NFκB signaling. [Abstract]

2024 Apr:126:155208. PMID: 38387275
Biomed Pharmacother

Oleanolic acid inhibits mouse spinal cord injury through suppressing inflammation and apoptosis via the blockage of p38 and JNK MAPKs. [Abstract]

2020 Mar;123:109752. PMID: 31924596
PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Chin Med

Discovery of an AKT1-targeting compound from a traditional herbal formula for alcoholic liver disease via integrative computational and experimental approaches. [Abstract]

2025 Oct 7;20(1):166. PMID: 41053833
Am J Chin Med

Identification of Flavonoid Compounds in Treating Alzheimer's Disease Based on Network Medicine Framework Strategy. [Abstract]

2025 Aug 30:1-32. PMID: 40884807
Int Immunopharmacol

Oleanolic acid alleviates intestinal injury after hepatic ischemia-reperfusion under steatosis via PPARG-dependent M2 macrophage polarization. [Abstract]

2026 Feb 15:171:116162. PMID: 41494252
Eur J Pharmacol

Actichinone, a new ursane triterpenoid from Actinidia chinensis roots, ameliorates NAFLD via the AMPK and NF-κB pathways. [Abstract]

2025 Jan 17:177276. PMID: 39828019
Int Immunopharmacol

Oleanolic acid alleviating ischemia-reperfusion injury in rat severe steatotic liver via KEAP1/NRF2/ARE. [Abstract]

2024 Jul 6:138:112617. PMID: 38972213
Drug Dev Res

Inhibition of Glutathione Pathway by Oleanolic Acid via PSAT1 Leads to Ferroptosis in Colorectal Cancer. [Abstract]

2025 May;86(3):e70097. PMID: 40320855
Sci Rep

Pomolic acid alleviates CCl4‑induced liver fibrosis in mice by suppressing β-arrestin 2-mediated pro-fibrotic macrophage polarization. [Abstract]

2026 Mar 31. PMID: 41917130
Sci Rep

Ursolic and oleanolic acids suppress MNNG induced malignant transformation of human gastric mucosal epithelium by regulating the PI3 K/AKT pathway. [Abstract]

2025 Jul 1;15(1):21623. PMID: 40594240
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Dev Biol

Tenascin-C-EGFR activation induces functional human satellite cell proliferation and promotes wound-healing of skeletal muscles via oleanic acid. [Abstract]

2023 Dec:504:86-97. PMID: 37758009
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363

Solvent & Solubility

In Vitro:

DMF : 45.45 mg/mL (99.52 mM; ultrasonic and warming and heat to 60°C)

DMSO : 5 mg/mL (10.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1896 mL

10.9481 mL

21.8962 mL

5 mM

0.4379 mL

2.1896 mL

4.3792 mL

10 mM

0.2190 mL

1.0948 mL

2.1896 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 0.5 mg/mL (1.09 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 0.5 mg/mL (1.09 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.5 mg/mL (1.09 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 2 mg/mL (4.38 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 10% Tween-80 in Saline

Solubility: 5 mg/mL (10.95 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhao X, et al. Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis. Mol Cell Biochem. 2015 Feb;400(1-2):1-7. [Content Brief]

[2]. Liu J, et al. Oleanolic acid inhibits proliferation and invasiveness of Kras-transformed cells via autophagy. J Nutr Biochem. 2014 Nov;25(11):1154-60. [Content Brief]

[3]. Liu J, et al. p38 MAPK signaling mediates mitochondrial apoptosis in cancer cells induced by oleanolic acid. Asian Pac J Cancer Prev. 2014;15(11):4519-25. [Content Brief]

[4]. Martín R, et al. Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease. J Mol Cell Cardiol. 2014 Jul;72:250-62. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / DMF	1 mM	2.1896 mL	10.9481 mL	21.8962 mL	54.7405 mL
	5 mM	0.4379 mL	2.1896 mL	4.3792 mL	10.9481 mL
	10 mM	0.2190 mL	1.0948 mL	2.1896 mL	5.4741 mL
DMF	15 mM	0.1460 mL	0.7299 mL	1.4597 mL	3.6494 mL
	20 mM	0.1095 mL	0.5474 mL	1.0948 mL	2.7370 mL
	25 mM	0.0876 mL	0.4379 mL	0.8758 mL	2.1896 mL
	30 mM	0.0730 mL	0.3649 mL	0.7299 mL	1.8247 mL
	40 mM	0.0547 mL	0.2737 mL	0.5474 mL	1.3685 mL
	50 mM	0.0438 mL	0.2190 mL	0.4379 mL	1.0948 mL
	60 mM	0.0365 mL	0.1825 mL	0.3649 mL	0.9123 mL
	80 mM	0.0274 mL	0.1369 mL	0.2737 mL	0.6843 mL

Keywords

Oleanolic acid

21 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Oleanolic acid

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Phosphatase Inhibitor Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Aging Natural Product Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Oleanolic acid

All MAP3K Isoforms

All Endogenous Metabolite Isoforms

All HIV Isoforms

Biological Activity

Chemical Information

Publications (21)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Oleanolic acid Related Classifications

Cat. No.: HY-N0156